Your browser doesn't support javascript.
loading
Blood biomarkers for assessment of mitochondrial dysfunction: An expert review.
Hubens, W H G; Vallbona-Garcia, A; de Coo, I F M; van Tienen, F H J; Webers, C A B; Smeets, H J M; Gorgels, T G M F.
Afiliação
  • Hubens WHG; University Eye Clinic Maastricht, Maastricht University Medical Center+, Maastricht, the Netherlands; Research School of Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands.
  • Vallbona-Garcia A; University Eye Clinic Maastricht, Maastricht University Medical Center+, Maastricht, the Netherlands; Research School of Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands; Department of Toxicogenomics, Maastricht University, Maastricht, the Netherlands. Electronic ad
  • de Coo IFM; Research School of Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands; Department of Toxicogenomics, Maastricht University, Maastricht, the Netherlands.
  • van Tienen FHJ; Research School of Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands; Department of Toxicogenomics, Maastricht University, Maastricht, the Netherlands.
  • Webers CAB; University Eye Clinic Maastricht, Maastricht University Medical Center+, Maastricht, the Netherlands.
  • Smeets HJM; Research School of Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands; Department of Toxicogenomics, Maastricht University, Maastricht, the Netherlands.
  • Gorgels TGMF; University Eye Clinic Maastricht, Maastricht University Medical Center+, Maastricht, the Netherlands; Research School of Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands. Electronic address: theo.gorgels@mumc.nl.
Mitochondrion ; 62: 187-204, 2022 01.
Article em En | MEDLINE | ID: mdl-34740866
ABSTRACT
Although mitochondrial dysfunction is the known cause of primary mitochondrial disease, mitochondrial dysfunction is often difficult to measure and prove, especially when biopsies of affected tissue are not available. In order to identify blood biomarkers of mitochondrial dysfunction, we reviewed studies that measured blood biomarkers in genetically, clinically or biochemically confirmed primary mitochondrial disease patients. In this way, we were certain that there was an underlying mitochondrial dysfunction which could validate the biomarker. We found biomarkers of three classes 1) functional markers measured in blood cells, 2) biochemical markers of serum/plasma and 3) DNA markers. While none of the reviewed single biomarkers may perfectly reveal all underlying mitochondrial dysfunction, combining biomarkers that cover different aspects of mitochondrial impairment probably is a good strategy. This biomarker panel may assist in the diagnosis of primary mitochondrial disease patients. As mitochondrial dysfunction may also play a significant role in the pathophysiology of multifactorial disorders such as Alzheimer's disease and glaucoma, the panel may serve to assess mitochondrial dysfunction in complex multifactorial diseases as well and enable selection of patients who could benefit from therapies targeting mitochondria.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Biomarcadores / Doenças Mitocondriais Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Mitochondrion Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Biomarcadores / Doenças Mitocondriais Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Mitochondrion Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda